SFPI-FPIM

Axelera AI focuses on providing specialized hardware and software platforms to enhance artificial intelligence tasks, particularly in edge computing. Its primary product, the Metis™ AI Platform, combines hardware and software to offer high-performance, energy-efficient AI inference solutions. The platform's innovative design has earned recognition as a CES® 2024 Innovation Awards Honoree. Established in 2021 after incubation by Bitfury and collaboration with imec, Axelera AI is headquartered in the AI Innovation Center at the High Tech Campus in Eindhoven, with research and development offices in Belgium, Switzerland, and Italy. The company's team comprises experts in AI from leading firms and Fortune 500 companies, focusing on delivering sustainable edge applications through a custom dataflow architecture and multicore in-memory computing that minimizes power consumption.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition traditionally managed through daily eye drop administration. EyeD Pharma aims to enhance the quality of life for patients by creating therapies that reduce side effects associated with existing treatments. In collaboration with ophthalmologists, the company offers new treatment options and surgical products, helping to improve clinical practices and provide therapeutic assistance that is currently lacking in the market.

PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens. PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Français du Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia. Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016.

ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

Endo Tools Therapeutics S.A. is a medical device company based in Gosselies, Belgium, founded in 2008. The company specializes in the development and manufacture of innovative therapeutic devices for gastroenterologists, focusing on flexible endoscopic interventions. Endo Tools Therapeutics is currently working on a catheter that will enhance therapeutic capabilities in interventional gastroenterology by adding therapeutic channels and degrees of freedom. The company's products aim to address conditions such as obesity, digestive tract tumors, and diabetes, enabling efficient surgical endoscopy through advanced techniques like flexible endoscopic suturing and tissue apposition. Additionally, the company has developed the ENDOMINA platform, which provides gastroenterologists with an open system for performing therapeutic procedures.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

ExeVir Bio BV, founded in 2020 and based in Zwijnaarde, Belgium, specializes in developing single-domain antibody-based therapies aimed at combating viral infections. The company leverages a llama-derived antibody technology platform to create robust antiviral treatments that offer broad protection against coronaviruses. Notably, it is developing VHH72-FC, an antibody that targets a highly conserved region on the spikes of SARS-CoV-2, crucial for the virus's entry into human cells. ExeVir Bio's rapid response platform for antivirals allows for an agile approach to emerging health threats, enabling the swift generation of drug candidates. The therapeutics produced through this innovative technology are designed to be stable, cost-effective, and accessible on a global scale.

iSTAR Medical SA was created in 2010 as a spinout of Healionics Corporation with support from Belgium's Region Wallonne government. In 2011, iSTAR expanded to its new eco-friendly R&D and Manufacturing facility in CREALYS Scientific Park near Namur, Belgium. By 2012, iSTAR received ISO 13485 and ISO 9001 Quality Systems Certifications and achieved CE Mark approval of its first device - STARflo™ Glaucoma Implant.

Ninepointfive is a venture capital investment firm based in Antwerp, Belgium, founded in 2017. It specializes in co-investing with corporate partners to support technology-based startups from pre-seed funding through to maturity. The firm collaborates with established brands to help founders maximize the value of corporate acceleration. Ninepointfive employs a proprietary methodology that emphasizes speed, growth, and active engagement, ensuring a pragmatic approach to investment. The firm's focus spans various sectors, including energy, financial services, healthcare, information technology, and both B2B and B2C markets.

Unifly is a drone traffic management software company focused on the safe integration of drones into the global airspace. Founded in 2015 by aerospace experts, the company emerged from a vision shared by air traffic controllers and engineers to manage the increasing presence of unmanned aircraft. Unifly's award-winning platform allows drone operators to check the legal status of their flights while enabling authorities to monitor and manage drone traffic effectively. The platform is currently utilized by national authorities in countries such as Germany, Denmark, Austria, and Belgium, and is also active in the United States and Africa. Unifly has established itself as a leader in unmanned traffic management technology, working collaboratively with various stakeholders, including research entities and businesses, to enhance airspace safety and efficiency. By providing essential tools for drone operators and regulators, Unifly aims to facilitate the seamless integration of drones into daily life while prioritizing safety and transparency.

ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

Endo Tools Therapeutics S.A. is a medical device company based in Gosselies, Belgium, founded in 2008. The company specializes in the development and manufacture of innovative therapeutic devices for gastroenterologists, focusing on flexible endoscopic interventions. Endo Tools Therapeutics is currently working on a catheter that will enhance therapeutic capabilities in interventional gastroenterology by adding therapeutic channels and degrees of freedom. The company's products aim to address conditions such as obesity, digestive tract tumors, and diabetes, enabling efficient surgical endoscopy through advanced techniques like flexible endoscopic suturing and tissue apposition. Additionally, the company has developed the ENDOMINA platform, which provides gastroenterologists with an open system for performing therapeutic procedures.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

Air Belgium S.A., founded in 1979 and based in Mont-Saint-Guibert, Belgium, provides passenger air transportation services primarily between Brussels and Hong Kong. The airline specializes in offering quality, attractively priced intercontinental flights to selected markets in Asia. Its fleet is equipped with economy, premium, and business class seating options, catering to diverse passenger needs, including provisions for traveling with pets and children. Additionally, Air Belgium enhances the travel experience through onboard catering services, ensuring that passengers enjoy comfortable and pleasant journeys.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

iSTAR Medical SA was created in 2010 as a spinout of Healionics Corporation with support from Belgium's Region Wallonne government. In 2011, iSTAR expanded to its new eco-friendly R&D and Manufacturing facility in CREALYS Scientific Park near Namur, Belgium. By 2012, iSTAR received ISO 13485 and ISO 9001 Quality Systems Certifications and achieved CE Mark approval of its first device - STARflo™ Glaucoma Implant.

Iteos Therapeutics S.A. is a biotechnology company focused on developing immuno-oncology therapeutics to treat cancer patients. Headquartered in Gosselies, Belgium, the company was established in 2011 and operates as a subsidiary of Iteos Therapeutics, Inc. Its product pipeline features EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing open-label Phase 1/2a clinical trials in adult patients. Another key candidate is EOS-448, an anti-TIGIT antibody, also in Phase 1/2a clinical trials. Iteos Therapeutics aims to address immune suppression in the tumor microenvironment by creating small molecule immunomodulators, thereby enhancing the effectiveness of existing cancer treatments and newer immunomodulatory therapies. The company leverages expertise from the Ludwig Cancer Research Institute in its efforts to advance cancer therapies.